Introducing the new interdisciplinary Karger journal

*Biomedicine Hub* is an interdisciplinary journal: a ‘hub’ for researchers, clinicians and public health professionals across biomedical disciplines to share research findings, ideas, theories, experimental results and clinical experience. *Biomedicine Hub* aims at facilitating the exchange of knowledge between disciplines, with a focus on translational science for the development of cutting-edge technologies and the improvement of health care. A further focus is on emerging interdisciplinary fields at the forefront of medicine.

Karger premium quality – open access – peer-reviewed – rapid publication

Get the full picture on [www.biomedicinehub.com](http://www.biomedicinehub.com)

- 16 internationally renowned senior editors
- over 170 Editorial Board Members
- from 35 countries
- specialized in 41 medical disciplines

**We invite you to submit now!**

Article Processing Charges (APC) are waived before June 30, 2016.

[www.karger.com/bmh_guidelines](http://www.karger.com/bmh_guidelines)

Visit us on Facebook
Contents

See the journal website for contents
Infl ammatory Intestinal Diseases

Aims and Scope
Imparting the most current information to physicians caring for patients with intestinal diseases, this journal seeks to identify the basic pathophysiological mechanisms common to different inflammatory intestinal diseases, to compare the environmental conditions involved in their pathogenesis, and to provide important insights into their therapies. Inflammatory Intestinal Diseases thus reduces the gap between clinical and basic sciences as well as between hepatology and inflammatory diseases of the intestinal tract such as inflammatory bowel diseases, celiac disease and irritable bowel syndrome. Infl ammatory Intestinal Diseases also aims to improve the exchange of knowledge between researchers from Eastern and Western countries, which is reflected in the composition of the Editorial Board. Special articles are prepared by two authors, one from East and one from West, which compare genetics, epidemiology, diagnostic methods, and treatment options of a disease. Apart from publishing original basic research articles, the journal also accepts randomized controlled clinical trials, observational studies, and cost-effectiveness analyses as well as commentary type and systematic reviews and consensus statements.

Submission
The Journal accepts invited Review Articles.

Manuscripts written in English should be submitted to:

Editorial Office Infl ammatory Intestinal Diseases
S. Karger AG
Ms. Ricardo Cueni
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 13 43
Fax +41 61 306 14 54
E-mail: e.cueni@karger.com

All manuscripts must be accompanied by a cover letter. Assurance should be given in the cover letter that the manuscript is not under simultaneous consideration by any other publication.

Invited Reviews
Invited Review Articles provide expert overviews of the latest clinical data and therapeutic regimens.

Length of Review Articles:
- Abstract: max. 300 words
- In text: approx. 4,000 words
- 2 tables
- 2 illustrations
- approx. 50 references

Conditions
All manuscripts are subject to editorial review. Manuscripts received under the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Infl ammatory Intestinal Diseases and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Peers-Review Policy
Infl ammatory Intestinal Diseases is a peer-reviewed journal. Our aim is to provide authors with fast and constructive feedback regarding their submitted manuscript. The Editors-in-Chief and international editorial board ensure a thorough and fair peer review and the highest scientific publishing standards. The Editors-in-Chief are responsible to maintain high-quality peer review of papers submitted to the journal.

Disclosure Statement
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Disclosure statements will be published at the end of the article.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research. Further, they should also state that animal experiments conform to institutional standards. Authors are required to declare the approval codes obtained from the corresponding ethical committee on human or animal research.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will betracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement
The manuscript should conform to the following order: title page, abstract and key words, body, acknowledgments, references, figure legends, tables and figures. Manuscripts should be written in high-quality English suitable for effective communication to a professional medical audience. For authors whose native language is not English, use of a professional language editing service (http://www.karger.com/Resources/Authors) prior to submission can help to avoid delays with the review process. All pages, including the figure legends, should be numbered in sequence, and the first author's name should appear at the upper right corner of each page. Papers not conforming to the journal style will be returned without review.

Title page: The first page of each paper should indicate a concise title of no more than 150 characters, all authors' names (first name and surname), authors' institutional affiliations, and a short title for use as running head.

Corresponding author: The exact postal address of author(s) to whom correspondence, proofs, and reprint requests should be sent, including the postal code, must be given at the bottom of the title page. Please also supply phone number and e-mail address.

Abstract of Review Articles: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Submit the abstract on a separate page. The abstract should be less than 300 words.

Key words: Following the abstract, an alphabetical list of five key words that reflect the content of the paper should be given.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in sequential Arabic numerals) should be prepared as separate files. Tables require a brief and concise heading. Figures require a legend, prepared as a separate page, after references. Please use scale markers for electron micrographs, and indicate the type of stain used. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors; Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.
Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the review article. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement: ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author’s Choice™ (Gold Open Access) articles, see Author’s Choice™.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

- Be linked to the final version on www.karger.com
- Include the following statement: ‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Vienna, Austria
October 15-19, 2016
Venue: Austria Center Vienna

Europe’s Largest Gastroenterology Congress
World-Renowned Experts
Postgraduate Teaching Programme
Clinical Trials Revisited
Live Endoscopy
Hands-On Training
Therapy Updates
Advances in Clinical GI & Hepatology

Translational/Basic Science
Guidelines in Clinical Practice
Innovative Poster Formats
Live Broadcasting
Hotspot Controversial Debates
High Audience Interaction

Find out more, visit www.ueg.eu/week

Registration includes free UEG Week 24/7 access
International Symposia and Workshops

Scientific Dialogue in the Interest of Therapeutic Progress

Workshop
Communication and System Relevance in Liver Damage and Regeneration
Düsseldorf, Germany
January 21 – 22, 2016

Symposium 201
Gut-Liver Interactions: From IBD to NASH
Innsbruck, Austria
March 11 – 12, 2016

Symposium 202
Evolving Therapies in Clinical Practice in IBD
Prague, Czech Republic
April 29 – 30, 2016

Symposium 203
XXIV International Bile Acid Meeting: Bile Acids in Health and Disease
Düsseldorf, Germany
June 17 – 18, 2016

Symposium 204
Clinical Hepatology Practice in 2016: From Science to Therapy
Birmingham, Great Britain
September 2 – 3, 2016

Symposium 205
New Treatment Targets in Gut and Liver Diseases
Lucerne, Switzerland
October 21 – 22, 2016

FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Tel.: +49 (0)761/1514-125
Fax: +49 (0)761/1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

2016
The introduction of anti-tumor necrosis factor (TNF) antibodies into the treatment of patients with IBD about fifteen years ago has dramatically improved the quality of life for patients with severe Crohn’s disease and ulcerative colitis. But despite the fact that this therapeutic approach has been around for quite some time, there has been no comprehensive overview to date. The book at hand aims to amend this shortcoming, presenting for the first time a thorough overview on TNF action, mechanisms of anti-TNF therapy, treatment strategies, side effects, monitoring, biosimilars and related issues. Including state-of-the-art information and research results, this publication will be a valuable source of information and guide clinicians to the optimal treatment decision, improving the quality of life of patients with IBD. Moreover, rheumatologists or even dermatologists might also find this book of interest.

Contents

- Preface: Rogler, G. et al.
  - Physiological Role of TNF in Mucosal Immunology
    - The Effect of TNF-α on the Regulation of Epithelial Function in IBD: Tsujiya, K.
    - Physiological Role of TNF in Mucosal Immunology: Regulation of Macrophage/Dendritic Cell Function: Rovillier, A. et al.
    - Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell Function: Scharl, M.
  - Pathophysiological Role of TNF in IBD
    - Pathophysiological Role of TNF in IBD: TNF and Its Impact on Barrier Function: Schumann, M.; Kühnel, A.
    - Pathophysiological Role of TNF in IBD: TNF and Its Effect on Innate Immune Defense: Scharl, M.
    - TNF and Its Impact on Adaptive Immune Mechanisms and Chronic Inflammation: Siegmund, B.
  - Mechanism of Action of Anti-TNF Antibodies
    - Binding of Membrane-Bound TNF: Atreya, R. et al.
    - Apoptosis of T Cells and Monocytes: Kucharzik, T.
    - Neutralisation of Soluble TNF: Dreessen, E.; Gils, A.
  - General Treatment Considerations
    - Recommended Screening Procedures before Treatment with Anti-TNF Agents: Maasor, C.
    - The Risk of Formation of Neutralising Antibodies: Clark, J.; Scharl, M.
    - TNF Antagonist Trough Concentrations and Treatment Efficacy in IBD: Vande Castelee, N.

Biosimilars

- What Is a Biosimilar? Neri, D.
- Is Extrapolation of Safety and Efficacy Data Possible? Ainsworth, M.
- Potential Concerns and Questions: Rogler, G.

Side Effects of Anti-TNF Therapy

- Psoriasis-Like Lesions and Skin Reactions: Herfarth, H.H. et al.
- The Elicitation of Rheumatic Symptoms at Vascular Sites: Geyer, M.; Müller-Ladner, U.
- Serum Reaction, Lupus-Like Syndrome: Schnitzler, F.

Risks of Anti-TNF Therapy

- Risk of Non-Hematologic Malignancy with Anti-TNF Therapy in IBD: Jain, A. et al.
- Risk of Lymphoma: Nagahori, M.; Watanabe, M.
- Risk of Serious Infection: Naganuma, M.
- Risk of Post-Operative Infections with Anti-TNF Therapy: Cohen, B.L.

Anti-TNF Therapy in Crohn’s Disease

- Predictor of Treatment Response: Tanaka, H.; Motoya, S.
- Step-Up or Top-Down, Combination with Immunosuppression or Not? Barthel, C.; Stange, E.F.

Anti-TNF Therapy in Ulcerative Colitis

- The ‘Ideal’ Anti-TNF Patient: Indications for Anti-TNF Therapy in Ulcerative Colitis: Hisamatsu, T.
- Predictors of the Treatment Response: Kim, H.J.
- What Is the Right Dosage? Michetti, P.

Anti-TNF Therapy in Special IBD Situations

- Fistulizing and Stricturing Crohn’s Disease: Schoepfer, A.M.
- Anti-TNF Therapy in Refractory Extraintestinal Manifestations of IBD: Nielsen, O.H. et al.
- Anti-TNF Therapy in Special Situations of the Patient
- Anti-TNF Alpha Agents and Breastfeeding: Al-Sum, H.; Maxwell, C.V.

When and How to Stop Anti-TNF Treatment in IBD

- When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment: Louis, E.
- Treatment Options after Anti-TNF Failure: Kobayashi, T.
The fifth revised edition of this highly successful book presents the most extensive enhancement since *Using and Understanding Medical Statistics* was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the ‘heavy lifting’.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

**Contents**

Preface to the Fifth Edition
Prefaces to the Previous Editions

- Basic Concepts
- Tests of Significance
- Fisher's Test for \(2 \times 2\) Contingency Tables
- Approximate Significance Tests for Contingency Tables
- Some Warnings concerning \(2 \times 2\) Tables
- Kaplan-Meier or 'Actuarial' Survival Curves
- The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
- An Introduction to the Normal Distribution
- Analyzing Normally Distributed Data
- Linear Regression Models for Medical Data
- Binary Logistic Regression
- Regression Models for Count Data
- Proportional Hazards Regression
- The Analysis of Longitudinal Data
- Analysis of Variance
- Data Analysis
  - The Question of Sample Size
  - The Design of Clinical Trials
  - Further Comments regarding Clinical Trials
  - Meta-Analysis
  - Epidemiological Applications
  - Diagnostic Tests
  - Agreement and Reliability

References
Subject Index
Digestion concentrates on clinical research reports: in addition to editorials and reviews, the journal features sections on Stomach/Esophagus, Bowel, Neuro-Gastroenterology, Liver/Bile, Pancreas, Metabolism/Nutrition and Gastrointestinal Oncology. Papers cover physiology in humans, metabolic studies and clinical work on the etiology, diagnosis, and therapy of human diseases. It is thus especially cut out for gastroenterologists employed in hospitals and outpatient units. Moreover, the journal’s coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.
Introducing the new interdisciplinary Karger journal

*Biomedicine Hub* is an interdisciplinary journal: a ’hub’ for researchers, clinicians and public health professionals across biomedical disciplines to share research findings, ideas, theories, experimental results and clinical experience. *Biomedicine Hub* aims at facilitating the exchange of knowledge between disciplines, with a focus on translational science for the development of cutting-edge technologies and the improvement of health care. A further focus is on emerging interdisciplinary fields at the forefront of medicine.

Karger premium quality – open access – peer-reviewed – rapid publication

Get the full picture on [www.biomedicinehub.com](http://www.biomedicinehub.com)

- **16** internationally renowned senior editors
- **over 170** Editorial Board Members
- **from 35** countries
- **specialized in 41** medical disciplines

*We invite you to submit now!*

Article Processing Charges (APC) are waived before June 30, 2016. [www.karger.com/bmh_guidelines](http://www.karger.com/bmh_guidelines)

Visit us on Facebook
Editorial

1 Inflammatory Intestinal Diseases: Why Do We Need Another Gastroenterology Journal?
    Rogler, G. (Zurich); Hibi, T. (Tokyo)

Liver and Gut: Reviews

3 Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?
    Nakamoto, N. (Tokyo); Schnabl, B. (La Jolla, Calif./San Diego, Calif.)

9 Ulcerative Colitis with and without Primary Sclerosing Cholangitis: Two Different Diseases?
    Tanaka, A. (Tokyo); Mertens, J.C. (Zurich)

15 Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences
    Nakase, H. (Kyoto); Herfarth, H. (Chapel Hill, N.C.)

24 Changes of Intestinal Functions in Liver Cirrhosis
    Fukui, H. (Kashiwara); Wiest, R. (Bern)

41 Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?
    Rieder, F. (Cleveland, Ohio); Bettenworth, D. (Münster); Imai, J.; Inagaki, Y. (Isehara)